Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Recruiting · NCT02523014 · Registry updated 2026-10-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, central nervous system cancer, intracranial meningioma, meningioma, neoplasm, nervous system disorder, tumor of meninges, vascular cancer | Recruiting | Phase 2 | 2026-10-02 | NCT02523014 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alliance for Clinical Trials in Oncology | 79 |
| Brain Science Foundation | 1 |
| Genentech, Inc. | 221 |
| GlaxoSmithKline | 294 |
| National Cancer Institute (NCI) | 3015 |
784 results · Page 1 of 32
Research sites
Swipe the table sideways for more columns.